Back to top

Novo Nordisk (NVO) Receives a Hold from BMO Capital

In a report released today, Evan Seigerman from BMO Capital reiterated a Hold rating on Novo Nordisk, with a price target of $47.00. According to T...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

NOV Inc. (NOV)

Novo Nordisk A/S (NVO)